Extended Data Fig. 3. Tumor volume monitoring and progression during radio-immunotherapy response in the PDG-Ink4a and PDG-p53 poorly-immunogenic glioblastoma models.
a,b, Distribution of PDG-Ink4a (a) and PDG-p53 (b) tumor volume measured by MRI imaging at the time of inclusion into treatment Cont, RT, IT, RT + Concurrent IT (RT + Conc.IT) and RT + Adj.IT (a, Cont n = 8, IT n = 8, RT n = 17, RT + Conc.IT n = 18, RT + Adj.IT n = 17 mice. b, Cont n = 8, IT n = 4, RT n = 15, RT + Conc.IT n = 17, RT + Adj.IT n = 18 mice). c-h, Longitudinal individual tumor volumes measured by weekly MRI in PDG-Ink4a (c-e) and PDG-p53 (f-h) tumor-bearing mice treated with Cont, IT, RT, RT + Conc.IT and RT + Adj.IT. Each line indicates the matched tumor progression per individual mouse (c-e: Cont n = 8, IT n = 8, RT n = 17, RT + Conc.IT n = 18, RT + Adj.IT n = 18 mice; f-h: Cont n = 8, IT n = 5, RT n = 18, RT + Conc.IT n = 22, RT + Adj.IT n = 17 mice). i, Tumor volume regression in PDG-Ink4a glioblastoma calculated by MRI at d7 and d14 in mice included in Cont, IT, RT, RT + Conc.IT and RT + Adj.IT treatment groups (d7 Cont n = 4, d7 IT n = 6, d7 RT n = 18, d7 RT + Conc.IT n = 22, d7 RT + Adj.IT n = 22, d14 RT n = 19, d14 RT + Conc.IT n = 23, d14 RT + Adj.IT n = 26 mice). j,k, Dot plot graphs depicting the correlation between PDG-Ink4a (j) and PDG-p53 (k) individual tumor volume at treatment inclusion and the animal overall survival in days (j: RT n = 17, RT + Conc.IT n = 17, RT + Adj.IT n = 17; k: RT n = 15, RT + Conc.IT n = 17, RT + Adj.IT n = 18). Data are represented as mean ± S.E.M. (a,b) or + S.E.M. (i).